Cassava Sciences (SAVA) to Release Earnings on Tuesday

Cassava Sciences (NASDAQ:SAVA) is projected to release its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect Cassava Sciences to post earnings of ($0.30) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 10:30 AM ET.

Cassava Sciences Stock Down 1.8%

Shares of NASDAQ SAVA opened at $2.24 on Monday. The company has a 50 day moving average of $2.12 and a 200 day moving average of $2.68. The firm has a market cap of $108.21 million, a P/E ratio of -1.02 and a beta of -0.85. Cassava Sciences has a twelve month low of $1.15 and a twelve month high of $4.98.

Institutional Investors Weigh In On Cassava Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in SAVA. Invesco Ltd. bought a new stake in Cassava Sciences during the fourth quarter valued at $36,000. Jump Financial LLC bought a new stake in shares of Cassava Sciences during the 2nd quarter worth $50,000. Price T Rowe Associates Inc. MD purchased a new position in Cassava Sciences in the 4th quarter worth about $63,000. Engineers Gate Manager LP increased its position in shares of Cassava Sciences by 121.1% in the fourth quarter. Engineers Gate Manager LP now owns 31,654 shares of the company’s stock worth $63,000 after acquiring an additional 17,335 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of Cassava Sciences by 53,154.9% during the 4th quarter. Barclays PLC now owns 48,462 shares of the company’s stock valued at $96,000 after buying an additional 48,371 shares during the period. 38.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Wall Street Zen lowered Cassava Sciences from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Cassava Sciences in a research report on Friday, December 26th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Cassava Sciences has a consensus rating of “Reduce” and a consensus price target of $2.00.

About Cassava Sciences

Cassava Sciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies and diagnostics for Alzheimer’s disease and related neurodegenerative disorders. Headquartered in Austin, Texas, the company was originally founded as Pain Therapeutics in 1998 and rebranded to Cassava Sciences in 2017. Cassava’s research program centers on small molecules designed to address underlying mechanisms of neurodegeneration rather than solely targeting amyloid plaques or tau tangles.

The company’s lead drug candidate, simufilam (formerly PTI-125), is a proprietary small molecule that aims to restore normal shape and function to the scaffolding protein filamin A, which has been implicated in impaired neuronal signaling and inflammation in Alzheimer’s patients.